Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this clinical research study is to examine the safety and effectiveness (how
well the drug works) of two different treatments for patients with melanoma. One treatment is
an investigational compound (a drug that is not currently approved by the United States Food
and Drug Administration [FDA]), know as Ipilimumab (also known as MDX-010 or BMS-734016)
together with an approved chemotherapy drug called Dacarbazine